Fresenius Medical Care AG & Co. (NYSE:FMS) announced an annual dividend on Thursday, May 9th, Wall Street Journal reports. Shareholders of record on Monday, May 20th will be given a dividend of 0.6551 per share on Friday, May 31st. This represents a yield of 1.59%. The ex-dividend date is Friday, May 17th. This is a positive change from Fresenius Medical Care AG & Co.’s previous annual dividend of $0.44.
Fresenius Medical Care AG & Co. has raised its dividend by an average of 12.7% per year over the last three years and has raised its dividend annually for the last 3 consecutive years. Fresenius Medical Care AG & Co. has a payout ratio of 17.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Fresenius Medical Care AG & Co. to earn $2.69 per share next year, which means the company should continue to be able to cover its $0.43 annual dividend with an expected future payout ratio of 16.0%.
FMS stock traded down $0.14 during midday trading on Thursday, reaching $41.17. 77,694 shares of the company were exchanged, compared to its average volume of 246,122. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.73. Fresenius Medical Care AG & Co. has a 1-year low of $30.99 and a 1-year high of $53.40. The stock has a market cap of $26.24 billion, a P/E ratio of 18.14, a PEG ratio of 2.91 and a beta of 1.40.
A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a report on Wednesday. Commerzbank reaffirmed a “hold” rating and issued a $54.00 target price on shares of Fresenius Medical Care AG & Co. in a report on Thursday. DZ Bank reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday. SunTrust Banks lifted their target price on shares of Fresenius Medical Care AG & Co. to $48.00 and gave the company a “positive” rating in a report on Thursday, February 21st. Finally, Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. Fresenius Medical Care AG & Co. presently has a consensus rating of “Hold” and a consensus price target of $61.33.
An institutional investor recently raised its position in Fresenius Medical Care AG & Co. stock. Geode Capital Management LLC boosted its position in Fresenius Medical Care AG & Co. (NYSE:FMS) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,854 shares of the company’s stock after buying an additional 1,367 shares during the period. Geode Capital Management LLC’s holdings in Fresenius Medical Care AG & Co. were worth $383,000 as of its most recent SEC filing. 1.90% of the stock is owned by institutional investors and hedge funds.
Fresenius Medical Care AG & Co. Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: Gross Domestic Product (GDP)
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.